lc350189
Small moleculeexperimental
Clinical trial activity
12 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Jun 1, 2011 (NCT01361646)
Timeline
Indications
Mechanism of action
- Xanthine dehydrogenaseINHIBITOR
XDH inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)n1cc(C#N)c2cc(-n3cc(C(=O)O)cn3)ccc21- Mol. weight
- 294.31 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3652780 ↗
Also known as
- lc350189
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06501534 | Phase 2 | Jul 10, 2024 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT06189404 | Phase 1 | Oct 31, 2023 | LG |
| NCT05586971 | Phase 3 | Jan 31, 2023 | LG |
| NCT05586958 | Phase 3 | Dec 31, 2022 | LG |
| NCT04966325 | Early Phase 1 (Phase 1) | Sep 15, 2021 | LG |
| NCT04886050 | Phase 1 | Aug 31, 2021 | LG |
| NCT04070846 | Phase 1 | Feb 28, 2020 | LG |
| NCT04139824 | Phase 1 | Jan 31, 2020 | LG |
| NCT04066712 | Phase 1 | Oct 31, 2019 | LG |
| NCT03934099 | Phase 2 | Oct 31, 2019 | LG |
| NCT03927677 | Phase 1 | Oct 30, 2019 | LG |
| NCT01361646 | Phase 1 | Jun 1, 2011 | LG, Seoul National University |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| LG | For profit | 11 | 11 | 3 | 2011 |
| Innovent Biologics (Suzhou) Co. Ltd. | For profit | 1 | 1 | 1 | 2024 |
| Seoul National University | Academic/Hospital | 1 | 0 | 1 | 2011 |
3 organizations
Page 1 / 1